Source: The New Consumer
GLP-1 adoption is moving beyond early adopters into mass-market territory. The drugs' cultural and commercial footprint will expand far beyond weight loss into mainstream health and wellness. Consumer brands, insurers, and food companies now face a different customer base—one where demand destruction in certain categories (ultra-processed foods, alcohol) becomes predictable rather than speculative, while new markets emerge around GLP-1-compatible nutrition and lifestyle products. The question shifts from efficacy to behavior: how does consumer culture normalize when 40 million Americans are on these drugs simultaneously.